





Radiology Interventional Surgery

EVOlution upgrade package: the continuous improvement program for your Esaote ultrasound system



MyLabevolution

- Image quality
- Easy workflow
- Advanced hemodynamic technology
- Comprehensive interventional packages and quantification tools
- Complete solution for urology
- Remote control and customizable keyboard
- Improved multimedia capabilities



MyLabClass C

MyLabTwice







MyLab evolution offers an incredible set of new tools

- **QElaXto** Shear Wave technology for Tissue Stiffness Quantitative Assessment (for MyLab™Twice)
- microV high sensitivity, high spatial resolution, high Frame rate hemodynamic analysis for micro-vascularization in tissue perfusion
- Wide angle on convex, linear, and microconvex probes for enlarged field of view
- ElaXto extension strain elastosonography package and measurements for multiple applications and probe typologies (EC1123, TRT33, SI2C41, LA332)
- Improved IQ on linear probes (LA533/ LA435)
- New ultra high fequency probe with elastosonography (SL2325)
- Reusable biopsy kit for high frequency linear probe LA533

- Stepper Grid for transperineal biopsies and treatments guidance for transrectal dual array probe with real-time Fusion Imaging option
- Contrast-enhanced Ultrasound CnTI™ **Ouantification Software**
- CnTI™ availability on microconvex probe (SC3123)
- MyLab™Remote 2.0 Remote system user interface app to control your MyLab™ system via smartphone or tablet
- MyLab™App for smart data transfer to mobile devices
- Exam pause/re-opening for improved workflow an dpatient throughput
- Real-time DICOM and connection improvements
- Uninterruptible Power Supply (UPS) option




microV hemodynamic analysis



Elaxto full-body



Top CnTl™ performance



Urology Fusion Imaging

Thank you for your trust in Esaote

We listen to your needs and work every day to provide the most advanced technologies and innovative design for you to excel in patient care.







Technology and features are system/configuration dependent. Specifications subject to change without notice. Information might refer to products or modalities not yet approved in all countries. CnTITM: The use of Contrast Agents in the USA is limited by FDA to the left ventricle opacification and to characterization of focal liver lesions. For further details, please contact your Esaote sales representative.